

Ms H Farrant
CANCER RESEARCH UK & UNIV. COLL. LONDON CANCER TRIALS CENTRE
90 TOTTENHAM COURT ROAD
LONDON
W1T 4TJ
UNITED KINGDOM

13/05/2010

Dear Ms H Farrant

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference: 20363/0204/001-0034
Eudract Number: 2004-002197-34
Product: Mabthera
Protocol number: 04/Q1104/27
Substantial Amendment Code Number: Amendment 7: Protocol V6.0, 26.03.2010

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 08/04/2010.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**